Analysis Of Income And Expense [Abstract]

GenSight Biologics S.A. - Filing #5982864

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
1 500 EUR
1,267,000 EUR
Material income and expense [abstract]
Research and development expense
12 368 EUR
19,360,000 EUR
Finance income (cost)
1 833 EUR
3,475,000 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
5 386 EUR
5,352,000 EUR
Revenue and other operating income
2 625 EUR
2,963,000 EUR
Operating expense
18 438 EUR
32,659,000 EUR
Sales and marketing expense
685,000 EUR
7,947,000 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
184,000 EUR
184,000 EUR
103,000 EUR
103,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
14 172 EUR
14 001 EUR
171,000 EUR
26,111,000 EUR
26,220,000 EUR
109,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.